---
title: "Quoin Pharmaceuticals Advances in Netherton Syndrome Treatment Study"
description: "Quoin Pharmaceuticals Ltd is conducting a clinical study on QRX003 lotion for treating Netherton syndrome, a genetic skin disorder. The study evaluates the lotion's effectiveness and safety over 12 we"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/262950637.md"
published_at: "2025-10-27T19:05:37.000Z"
---

# Quoin Pharmaceuticals Advances in Netherton Syndrome Treatment Study

> Quoin Pharmaceuticals Ltd is conducting a clinical study on QRX003 lotion for treating Netherton syndrome, a genetic skin disorder. The study evaluates the lotion's effectiveness and safety over 12 weeks, focusing on symptom improvement. It began on April 7, 2025, and is currently recruiting participants. Positive results could enhance Quoin's market position and influence its stock performance, given the niche market for Netherton syndrome treatments.

Quoin Pharmaceuticals Ltd is conducting a clinical study titled ‘A Single Center, Open Label, Expanded Access Study of QRX003 Lotion in Subjects With Netherton Syndrome.’ The study aims to evaluate the effectiveness and safety of QRX003, a topical lotion, in treating Netherton syndrome, a genetic skin disorder. The primary objectives are to assess the improvement in clinical symptoms and identify any medical issues arising from the treatment.

The intervention being tested is QRX003, a 4% topical lotion applied twice daily. It is designed to alleviate symptoms of Netherton syndrome by acting as a serine protease inhibitor.

This open-label study follows a single-group intervention model without masking. Its primary purpose is treatment, focusing on the direct application of QRX003 to affected areas, excluding the scalp, over a 12-week period.

The study began on April 7, 2025, with the latest update submitted on July 16, 2025. These dates are crucial as they mark the study’s progress and ongoing recruitment status.

The study’s progress could influence Quoin Pharmaceuticals’ stock performance, as successful results might boost investor confidence. Given the niche market for Netherton syndrome treatments, positive outcomes could position Quoin as a leader in this area, potentially impacting competitors.

The study is currently recruiting, with further details available on the ClinicalTrials portal.

### Related Stocks

- [QNRX.US - Quoin Pharmaceuticals](https://longbridge.com/en/quote/QNRX.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 奥运会 - 速度滑冰 - 荷兰选手 Kok 在米兰科尔蒂纳的 500 米比赛中展现了她的统治力，赢得金牌 | 世界纪录保持者 Femke Kok 在米兰 - 科尔蒂纳冬奥会上赢得女子 500 米金牌，为荷兰赢得了第二个速滑项目的冠军。Kok 以 36.49 秒的奥运纪录时间完赛，比同胞 Jutta Leerdam 快了 0.66 秒，后者获得银牌。 | [Link](https://longbridge.com/en/news/276010598.md) |
| 在新的遗传性血管性水肿数据发布和会议聚焦之后，审视 BioCryst 制药（BCRX）的估值 | BioCryst Pharmaceuticals (BCRX) 在一场重要的过敏会议上宣布了九个遗传性血管性水肿的报告，引起了关注，其中包括 navenibart 的积极中期数据。尽管最近股价在一天内上涨了 4.43%，但该股票年初至今已下 | [Link](https://longbridge.com/en/news/275698599.md) |
| 诺华制药向 FDA 提交了 remibrutinib 用于治疗症状性皮肤划痕症的补充新药申请（sNDA） | 诺华制药（Novartis AG）已向 FDA 提交了口服瑞米布替尼（remibrutinib）的补充新药申请（sNDA），旨在治疗症状性皮肤划痕症，这是一种慢性诱发性荨麻疹。此次提交是在瑞米布替尼在三种慢性诱发性荨麻疹（CIndU）类型的 | [Link](https://longbridge.com/en/news/276201044.md) |
| 美国因病毒爆发对这些岛屿发布旅行建议 | 美国疾病控制与预防中心（CDC）已对塞舌尔发布了 “二级” 旅行警告，原因是出现了基孔肯雅病毒疫情。旅行者被敦促采取增强的预防措施，包括接种疫苗和防止蚊虫叮咬。基孔肯雅病毒的症状包括发热和关节疼痛，部分患者会经历慢性疼痛。孕妇被建议重新考虑 | [Link](https://longbridge.com/en/news/275778861.md) |
| 一种通过性传播的癣正在美国的一个州扩散 | 明尼苏达州正在经历美国最大规模的性传播环状癣（TMVII）疫情，自七月以来已报告超过 30 例确诊或疑似病例。该感染主要影响男性同性恋者，可能导致疼痛和瘙痒的皮疹。治疗可能需要数周或数月，卫生官员建议在皮疹出现时避免性接触。TMVII 通过 | [Link](https://longbridge.com/en/news/275977276.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.